{"id":"W2883673963","doi":"10.1016/s1470-2045(18)30343-7","title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Internal medicine; Olaparib; Tolerability; Quality of life (healthcare); Placebo; Clinical endpoint; Oncology; Ovarian cancer; Adverse effect; Nausea; Progression-free survival; Randomized controlled trial; Cancer; Chemotherapy; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001123949,0.001291806,0.002470282,0.0002832216,0.0003233406,0.001036042,0.0006766205,0.001494509,0.00338369],"category_scores_gemma":[0.001642046,0.0004851796,0.002666825,0.0004205295,0.0009130777,0.0008550114,0.0004641914,0.002920856,0.0003546878],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007743041,"about_ca_system_score_gemma":0.00060615,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009107839,"about_ca_topic_score_gemma":0.001455144,"domain_scores_codex":[0.9994082,0.0003126075,0.00004482555,0.0001068081,0.00003662422,0.00009093884],"domain_scores_gemma":[0.999118,0.0002924352,0.0002639549,0.00006111324,0.00003407854,0.000230389],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9796793,0.002268189,0.001727765,0.0006352472,0.001699381,0.0000284716,0.00004132641,0.0003480582,0.0009084973,0.00005265468,0.0002959845,0.01231515],"study_design_scores_gemma":[0.8965965,0.0872492,0.01206868,0.0001045712,0.002093796,0.00005320553,0.0000506361,0.000601156,0.0003477971,0.000253713,0.0005502886,0.00003037788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914054,0.006258036,0.0001684457,0.000390807,0.0002041157,0.0004571075,0.0004260775,0.00002627629,0.0006638549],"genre_scores_gemma":[0.9957722,0.001695064,0.0002999985,0.0003473551,0.0001915904,0.0005763735,0.0004512203,0.000005709962,0.0006606104],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00338369,"threshold_uncertainty_score":0.01131958,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02878310592264365,"score_gpt":0.3335244201553895,"score_spread":0.3047413142327459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}